MEDAPP S.A. ZY -10 (WQ1) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MEDAPP S.A. ZY -10 (WQ1) has a cash flow conversion efficiency ratio of 0.076x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€2.04 Million ≈ $2.39 Million USD) by net assets (€26.82 Million ≈ $31.35 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See WQ1 net asset quality score to measure how much of total assets are equity-financed.
MEDAPP S.A. ZY -10 - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how MEDAPP S.A. ZY -10's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check WQ1 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
MEDAPP S.A. ZY -10 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MEDAPP S.A. ZY -10 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
JIADE LIMITED Common stock
NASDAQ:JDZG
|
0.040x |
|
Foresight Group Holdings Limited
LSE:FSG
|
0.305x |
|
Culpeo Minerals Ltd
AU:CPO
|
-0.105x |
|
Spacetalk Ltd
AU:SPA
|
-0.153x |
|
Torq Resources Inc
V:TORQ
|
0.340x |
|
ExGen Resources Inc
V:EXG
|
-0.168x |
|
Longvie SA
BA:LONG
|
-0.060x |
|
Sentra Food Indonesia Tbk PT
JK:FOOD
|
-0.117x |
Annual Cash Flow Conversion Efficiency for MEDAPP S.A. ZY -10 (2021–2025)
The table below shows the annual cash flow conversion efficiency of MEDAPP S.A. ZY -10 from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see WQ1 market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €26.82 Million ≈ $31.35 Million |
€2.44 Million ≈ $2.85 Million |
0.091x | -37.13% |
| 2024-12-31 | €28.84 Million ≈ $33.71 Million |
€4.17 Million ≈ $4.87 Million |
0.144x | +391.16% |
| 2023-12-31 | €26.73 Million ≈ $31.25 Million |
€-1.33 Million ≈ $-1.55 Million |
-0.050x | -123.57% |
| 2022-12-31 | €27.19 Million ≈ $31.79 Million |
€5.72 Million ≈ $6.69 Million |
0.210x | +1315.77% |
| 2021-12-31 | €25.25 Million ≈ $29.52 Million |
€-437.00K ≈ $-510.90K |
-0.017x | -- |
About MEDAPP S.A. ZY -10
MedApp S.A. engages in the development of solutions to support imaging diagnostics and digital medicine in Poland, rest of the European Union, and internationally. The company offers CarnaLife Holo, a technology for 3D visualization of imaged medical data which supports the planning and performance of medical procedures. HoloComm, an innovative solution for easy and convenient work on files in 3D… Read more